Advent Life Sciences — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.
BiotechCambridge, GB
Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)in
Co-investorsNovartis Venture FundSV Health InvestorsDementia Discovery FundEuropean Investment FundForbionGilde Healthcare+2 more
BiotechBoston, US
Dr. Richard Peters(Director)Belinda Termeer(Director)Dr. Alan E. Walts(Director)inDr. Gerhard Wagner(Director)Sun Altbach(Executive Officer, Director)in
Co-investorsLumira VenturesOrbiMed
Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.
BiotechDigital HealthHealthtechMedical Devices
Moin Saleem(Co-founder & Chief Scientific Advisor)in
Co-investorsSofinnova PartnersForbionGilde HealthcareBritish Patient Capital
Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investorsNovartis Venture FundNovo Holdings
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.